The 2003 Healthcare Conference 5-7 October 2003 Scarman House, The University of Warwick.
-
Upload
daniel-melton -
Category
Documents
-
view
215 -
download
1
Transcript of The 2003 Healthcare Conference 5-7 October 2003 Scarman House, The University of Warwick.
The 2003 Healthcare Conference
5-7 October 2003
Scarman House, The University of Warwick
Critical Illness
Why reviewable rates are more appropriate.
Bill Baker
Swiss Re Life & Health
Key Points
Guarantees cannot be provided at a fair price
We are insurers not bookmakers
Reviewable does not mean “no risk”
The right product at the right price
So what’s the right price for guarantees?
Average market price
90100110120130140150160
Ind
ex
Source: Average of 8 providers. M30NS, F30 NS, 25 year, £100,000 level cover
With every price increase more people become financially excluded
It’s tough getting the right price!
Variability of company experience Company A: 100 Company B: 170 Distribution? Social class mix? Underwriting? Claims
control?
IBNR A record? 77 months between claim event and notification to
the insurer
Do we really have sufficient volume of data?
Good foundations?
50
60
70
80
90
100
110
120
130
0 1 2 3 4 5
Duration
Rel
ativ
e va
lue
Observed
Expected
Reality?
Quality of our data?
Are we treating death claims correctly? Our split between accelerated and stand alone? The right claim date?
Date of diagnosis, notification, acceptance, settlement? What date did the HCSG use? What date does CMI use? What date do you use for experience studies?
What about substandard business? What about differences in scope of cover? What about population data?
How may the future change?
Impact of troponin: 2-3% increase in claims? Cancer screening:
NMP 48 Prostate cancer test Bowel cancer screening Breast cancer screening
Ombudsman’s decisions
Aims of medical science
Want to spot nasty conditions sooner Want to improve the outcome if you’re unlucky Want to stop nasty conditions happening
Good news for all of us Good news for life assurance Mixed news for critical illness!
Genetics and cancer
2002: Single gene test 2003: Total Genotyping 2007: Early treatments developed 2017: Treatments implemented 2025+: A cancer cure?
What do we really want?
Access to insurance
Competitive premium rates
Equity between policyholders
Keep withinmorbidity assumptions
Benefits to policyhold
er
Spread the risk
Benefits to Insurers
Accurate and sustainable
pricing
Shared risk
What do guaranteed rates give us?
Uncertainty about where we are Guessing about what will happen at the longer
durations Trying to second guess medical changes Predicting future actions of the Ombudsman Is 60% increase too much or too little? Rip off Britain? Get the price too low and solvency suffers and all
prices have to rise Insurance or gambling?
With every price increase more people become financially excluded
Reviewable does not mean “no risk”
Rates should be set to be sustainable over the product term
Review looking forward
Any past loses should not be passed on to the policyholder
Right product for the right price!
If it’s not broken don’t fix it!
Are we covering the right events?
Reviewable definitions?
Consumer choice: Increase premiums or change cover?
Why reviewable rates?
There is no right price for the unknown Every price increase more people are financially
excluded Critical today, routine tomorrow? Indemnity insurance or windfall gamble? Are we insurers or bookmakers?